Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice

Blood. 2014 Oct 30;124(18):2847-57. doi: 10.1182/blood-2014-03-564609. Epub 2014 Sep 4.

Abstract

Emerging evidence indicates that innate immunodeficiency syndromes are linked to mutations in innate receptors and to specific infections. X-linked lymphoproliferative syndrome type-2 (XLP-2) is associated with deficiency in X-linked inhibitor of apoptosis protein (XIAP), with poorly understood molecular mechanisms. Here we showed that XIAP deficiency selectively impaired B-cell chronic lymphocytic leukemia/lymphoma 10 (BCL10)-mediated innate responses to dectin-1 ligands but did not affect responses to various Toll-like receptor agonists. Consequently, Xiap(-/-) mice became highly vulnerable on Candida albicans infection. The compromised early innate responses led to the persistent presence of C albicans and inflammatory cytokines in Xiap(-/-) mice. Furthermore, priming of Xiap(-/-) mice with the dectin-1 ligand curdlan alone resulted in XLP-2-like syndromes. Restoration of dectin-1-induced Rac1 activation and phagocytosis by resolvin D1, but not up-regulation of nuclear factor-κB, rescued Xiap(-/-) mice from C albicans lethal infection. Therefore, development of XLP-2 in XIAP-deficient patients could be partly due to sustained inflammation as a consequence of defective BCL10-dependent innate immunity toward specific pathogens. Importantly, our results suggest the potential therapeutic value of resolvin D1 in the treatment of XLP-2 and innate immunodeficiency syndromes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Animals
  • B-Cell CLL-Lymphoma 10 Protein
  • Candida albicans / drug effects
  • Candida albicans / physiology
  • Candidiasis / immunology*
  • Candidiasis / microbiology
  • Candidiasis / pathology*
  • ErbB Receptors / metabolism
  • Genetic Diseases, X-Linked / immunology
  • Genetic Diseases, X-Linked / pathology
  • Humans
  • Imidazoles / pharmacology
  • Immunity, Innate* / drug effects
  • Inhibitor of Apoptosis Proteins / deficiency*
  • Inhibitor of Apoptosis Proteins / metabolism
  • Lectins, C-Type / agonists
  • Lectins, C-Type / metabolism
  • Lipopeptides / pharmacology
  • Lipopolysaccharides / pharmacology
  • Lymphoproliferative Disorders / immunology
  • Lymphoproliferative Disorders / pathology
  • Lysine / metabolism
  • Lysophospholipids / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mice
  • NF-kappa B / metabolism
  • Phagocytosis / drug effects
  • Poly I-C / pharmacology
  • Protein Binding / drug effects
  • Receptors, Antigen, T-Cell / metabolism
  • Toll-Like Receptors / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology
  • Ubiquitination / drug effects
  • beta-Glucans

Substances

  • Adaptor Proteins, Signal Transducing
  • B-Cell CLL-Lymphoma 10 Protein
  • Bcl10 protein, mouse
  • Birc4 protein, mouse
  • Imidazoles
  • Inhibitor of Apoptosis Proteins
  • Lectins, C-Type
  • Lipopeptides
  • Lipopolysaccharides
  • Lysophospholipids
  • NF-kappa B
  • Pam(3)CSK(4) peptide
  • Receptors, Antigen, T-Cell
  • Toll-Like Receptors
  • Tumor Necrosis Factor-alpha
  • beta-Glucans
  • dectin 1
  • curdlan
  • ErbB Receptors
  • Lysine
  • Poly I-C
  • lysophosphatidic acid
  • resiquimod

Supplementary concepts

  • Lymphoproliferative Syndrome, X-Linked, 2